Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous mesenchymal stem cell therapy - Pharmicell

Drug Profile

Autologous mesenchymal stem cell therapy - Pharmicell

Alternative Names: Cellgram; Cellgram-ED; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC 1 - FCB Pharmicell; MSC 2 - FCB Pharmicell

Latest Information Update: 01 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FCB-Pharmicell
  • Developer Asan Medical Center; Nonindustrial source; Pharmicell; Samsung Medical Center; Yonsei University Health System
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Stroke
  • Phase II/III Spinal cord injuries
  • Phase II Adult respiratory distress syndrome; Liver cirrhosis
  • Phase I/II Graft-versus-host disease; Parkinson's disease; Renal transplant rejection
  • No development reported Brain injuries; Cerebral haemorrhage; Erectile dysfunction; Pulmonary fibrosis; Solid tumours

Most Recent Events

  • 20 Jun 2019 Phase-I clinical trials in Liver cirrhosis in USA (Intra-arterial) (NCT03838250)
  • 28 May 2019 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in South Korea (Parenteral, Injection)
  • 22 Mar 2019 Pharmicell withdraws its phase I trial for Peripheral arterial disorders (in patients with critical limb ischaemia) in South Korea prior to enrolment due to sponsers internal reason (NCT02477540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top